Simultaneous pancreas-kidney transplantation at the University of Pittsburgh.

R. Shapiro, M. L. Jordan, V. P. Scantlebury, C. A. Vivas, Ashokkumar Jain, P. Chakrabarti, J. McCauley, J. Johnston, P. Randhawa, A. Rao, J. J. Fung, R. J. Corry

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Analysis of the SPK program at the University of Pittsburgh has led to a number of observations: 1. Under tacrolimus-based immunosuppression, without antibody induction, it has been possible to achieve (a) One- and 3-year actuarial patient survival rates of 98% and 95% (b) One- and 3-year actuarial kidney survival rates of 95% and 87% (c) One- and 3-year actuarial pancreas survival rates of 86% and 80% 2. Steroid withdrawal has been achieved in over half of the successfully transplanted recipients, with excellent outcomes and a low rate (4.7%) of subsequent rejection. 3. Bone marrow augmentation has been associated with (a) less rejection (b) less pancreatic graft loss to rejection (c) an increased ability to withdraw steroids 4. Rejection has been associated with a rising serum lipase. 5. Renal allograft rejection in SPK patients with elevated serum lipase levels has been seen in the setting of normal renal function. 6. Enteric drainage has been associated with a reasonably low complication rate. 7. SPK transplantation is a successful therapeutic option in selected type I diabetics with end-stage renal disease.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalClinical transplants
StatePublished - Jan 1 1999

Fingerprint

Pancreas Transplantation
Kidney Transplantation
Survival Rate
Lipase
Kidney
Steroids
Tacrolimus
Serum
Immunosuppression
Chronic Kidney Failure
Allografts
Drainage
Pancreas
Transplantation
Bone Marrow
Transplants
Antibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Shapiro, R., Jordan, M. L., Scantlebury, V. P., Vivas, C. A., Jain, A., Chakrabarti, P., ... Corry, R. J. (1999). Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. Clinical transplants, 217-221.
Shapiro, R. ; Jordan, M. L. ; Scantlebury, V. P. ; Vivas, C. A. ; Jain, Ashokkumar ; Chakrabarti, P. ; McCauley, J. ; Johnston, J. ; Randhawa, P. ; Rao, A. ; Fung, J. J. ; Corry, R. J. / Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. In: Clinical transplants. 1999 ; pp. 217-221.
@article{cc932c396fe846b3bf207374b65e88bb,
title = "Simultaneous pancreas-kidney transplantation at the University of Pittsburgh.",
abstract = "Analysis of the SPK program at the University of Pittsburgh has led to a number of observations: 1. Under tacrolimus-based immunosuppression, without antibody induction, it has been possible to achieve (a) One- and 3-year actuarial patient survival rates of 98{\%} and 95{\%} (b) One- and 3-year actuarial kidney survival rates of 95{\%} and 87{\%} (c) One- and 3-year actuarial pancreas survival rates of 86{\%} and 80{\%} 2. Steroid withdrawal has been achieved in over half of the successfully transplanted recipients, with excellent outcomes and a low rate (4.7{\%}) of subsequent rejection. 3. Bone marrow augmentation has been associated with (a) less rejection (b) less pancreatic graft loss to rejection (c) an increased ability to withdraw steroids 4. Rejection has been associated with a rising serum lipase. 5. Renal allograft rejection in SPK patients with elevated serum lipase levels has been seen in the setting of normal renal function. 6. Enteric drainage has been associated with a reasonably low complication rate. 7. SPK transplantation is a successful therapeutic option in selected type I diabetics with end-stage renal disease.",
author = "R. Shapiro and Jordan, {M. L.} and Scantlebury, {V. P.} and Vivas, {C. A.} and Ashokkumar Jain and P. Chakrabarti and J. McCauley and J. Johnston and P. Randhawa and A. Rao and Fung, {J. J.} and Corry, {R. J.}",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
pages = "217--221",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

Shapiro, R, Jordan, ML, Scantlebury, VP, Vivas, CA, Jain, A, Chakrabarti, P, McCauley, J, Johnston, J, Randhawa, P, Rao, A, Fung, JJ & Corry, RJ 1999, 'Simultaneous pancreas-kidney transplantation at the University of Pittsburgh.', Clinical transplants, pp. 217-221.

Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. / Shapiro, R.; Jordan, M. L.; Scantlebury, V. P.; Vivas, C. A.; Jain, Ashokkumar; Chakrabarti, P.; McCauley, J.; Johnston, J.; Randhawa, P.; Rao, A.; Fung, J. J.; Corry, R. J.

In: Clinical transplants, 01.01.1999, p. 217-221.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Simultaneous pancreas-kidney transplantation at the University of Pittsburgh.

AU - Shapiro, R.

AU - Jordan, M. L.

AU - Scantlebury, V. P.

AU - Vivas, C. A.

AU - Jain, Ashokkumar

AU - Chakrabarti, P.

AU - McCauley, J.

AU - Johnston, J.

AU - Randhawa, P.

AU - Rao, A.

AU - Fung, J. J.

AU - Corry, R. J.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Analysis of the SPK program at the University of Pittsburgh has led to a number of observations: 1. Under tacrolimus-based immunosuppression, without antibody induction, it has been possible to achieve (a) One- and 3-year actuarial patient survival rates of 98% and 95% (b) One- and 3-year actuarial kidney survival rates of 95% and 87% (c) One- and 3-year actuarial pancreas survival rates of 86% and 80% 2. Steroid withdrawal has been achieved in over half of the successfully transplanted recipients, with excellent outcomes and a low rate (4.7%) of subsequent rejection. 3. Bone marrow augmentation has been associated with (a) less rejection (b) less pancreatic graft loss to rejection (c) an increased ability to withdraw steroids 4. Rejection has been associated with a rising serum lipase. 5. Renal allograft rejection in SPK patients with elevated serum lipase levels has been seen in the setting of normal renal function. 6. Enteric drainage has been associated with a reasonably low complication rate. 7. SPK transplantation is a successful therapeutic option in selected type I diabetics with end-stage renal disease.

AB - Analysis of the SPK program at the University of Pittsburgh has led to a number of observations: 1. Under tacrolimus-based immunosuppression, without antibody induction, it has been possible to achieve (a) One- and 3-year actuarial patient survival rates of 98% and 95% (b) One- and 3-year actuarial kidney survival rates of 95% and 87% (c) One- and 3-year actuarial pancreas survival rates of 86% and 80% 2. Steroid withdrawal has been achieved in over half of the successfully transplanted recipients, with excellent outcomes and a low rate (4.7%) of subsequent rejection. 3. Bone marrow augmentation has been associated with (a) less rejection (b) less pancreatic graft loss to rejection (c) an increased ability to withdraw steroids 4. Rejection has been associated with a rising serum lipase. 5. Renal allograft rejection in SPK patients with elevated serum lipase levels has been seen in the setting of normal renal function. 6. Enteric drainage has been associated with a reasonably low complication rate. 7. SPK transplantation is a successful therapeutic option in selected type I diabetics with end-stage renal disease.

UR - http://www.scopus.com/inward/record.url?scp=0033288335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033288335&partnerID=8YFLogxK

M3 - Article

C2 - 11038640

AN - SCOPUS:0033288335

SP - 217

EP - 221

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -

Shapiro R, Jordan ML, Scantlebury VP, Vivas CA, Jain A, Chakrabarti P et al. Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. Clinical transplants. 1999 Jan 1;217-221.